These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21812538)

  • 1. The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.
    Hawkes EA; Wotherspoon A; Cunningham D
    Leuk Lymphoma; 2012 Mar; 53(3):354-61. PubMed ID: 21812538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
    Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
    Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
    Eichenauer DA; Engert A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment strategy of Hodgkin lymphoma].
    Nagai H
    Rinsho Ketsueki; 2014 Oct; 55(10):1941-51. PubMed ID: 25297759
    [No Abstract]   [Full Text] [Related]  

  • 6. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modern management of lymphocyte-predominant Hodgkin lymphoma.
    Xing KH; Savage KJ
    Br J Haematol; 2013 May; 161(3):316-29. PubMed ID: 23398605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
    van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
    Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
    Unal A; Sari I; Deniz K; Ozkan M; Kontas O; Eser B; Cetin M
    Leuk Lymphoma; 2005 Nov; 46(11):1613-7. PubMed ID: 16236615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
    Farrell K; McKay P; Leach M
    Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of lymphocyte-predominant Hodgkin lymphoma.
    Engert A
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv45-6. PubMed ID: 18519402
    [No Abstract]   [Full Text] [Related]  

  • 12. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
    Fanale M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
    Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
    Keilholz U; Szelényi H; Siehl J; Foss HD; Knauf W; Thiel E
    Leuk Lymphoma; 1999 Nov; 35(5-6):641-2. PubMed ID: 10609806
    [No Abstract]   [Full Text] [Related]  

  • 16. Nodular lymphocyte-predominant hodgkin lymphoma.
    Tsai HK; Mauch PM
    Semin Radiat Oncol; 2007 Jul; 17(3):184-9. PubMed ID: 17591565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma.
    Maraldo MV; Aznar MC; Vogelius IR; Petersen PM; Specht L
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1057-65. PubMed ID: 23200817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Spinner MA; Varma G; Advani RH
    Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.
    Honda A; Nakamura F; Nannya Y; Shintani Y; Fukayama M; Ichikawa M; Kurokawa M
    Ann Hematol; 2014 Jun; 93(6):1073-4. PubMed ID: 24173088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.